Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 16;23(4):2201. doi: 10.3390/ijms23042201

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of losartan, mirabegron, and their combination on morphological changes and systolic dysfunction in DOXO-induced chronic cardiotoxicity assessed by echocardiography at week 8. Values are presented as mean ± S.E.M., * p < 0.05 vs. control group, # p < 0.05 vs. DOXO-only group (n = 6–9, one-way ANOVA, Holm-Sidak post hoc test). (a) Representative M-mode images, (b) systolic septal wall thickness (SWTs), (c) systolic inferior wall thickness (IWTs), (d) left ventricular end-systolic diameter (LVESD), (e) left ventricular end-diastolic diameter (LVEDD), (f) fractional shortening (FS), and (g) ejection fraction (EF). DOXO: doxorubicin, L: losartan, M: mirabegron.